ClinicalTrials.Veeva

Menu

The Expression of TLR2 and TLR4 in the Lung of Chronic Obstructive Pulmonary Disease (COPD) Patients

Seoul National University logo

Seoul National University

Status

Unknown

Conditions

COPD
Smoking

Study type

Observational

Funder types

Other

Identifiers

NCT01226199
TLR2 and TLR4 in COPD tissue

Details and patient eligibility

About

Smoking is the most important risk factor of COPD, but only a fourth of smokers had COPD in their life. There are also healthy smokers without evidence of COPD. Investigators hypothesize that innate immunity may affect this difference between COPD patients and healthy smokers, because TLR4 is the receptor of LPS, which is the one of important substance in cigarette. Investigators will measure TLR2 and TLR4 expression in lung tissue of patients whose lung will be resected. Investigators will compare the level of expression between COPD patients and healthy smokers.

Enrollment

60 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients who will have lung resection for the therapeutic cause.

Exclusion criteria

  • Patients who do not agree with our study protocol

Trial contacts and locations

1

Loading...

Central trial contact

Sei Won Lee, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems